Century Therapeutics Inc.

IPSC | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.91

+$0.06 (+3.24%)

Sep 22, 2026, 11:06 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+3.24%

(1D)

Rating

Updated: Sep 11, 2026

Fundamentals Average

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $165.35M

1D Range

1.86 1.94

52W Range

0.44 3.04

Valuation (TTM)

PE -1.78

PB 0.69

EV/EBITDA -0.79

Valuation (NTM)

Forward PE N/A

Forward PEG 0.12

Price Target $7.50

Cash Flow

FCF Yield -55.3%

SBC Adj. FCF Yield -58.8%

SBC Impact -6.3%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -2.6% | 42.5%

Dil EPS 3Y | 5Y 44.1% | 26.8%

FCF 3Y | 5Y 6.8% | -11.1%

Returns

ROA -38.3%

ROE -52.8%

ROIC -43.7%

Financial Health

Net Cash

$119.71M

Current Ratio 8.28

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's for...

Sector Healthcare

Industry Biotechnology

Employees 78

IPO Date Jun 17, 2021

Website www.centurytx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 12, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$4.50

Upside

+135.60%

Buy (2)

Hold (1)

Sell (0)

Analyst Details ➞